ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
ArriVent reported initial Phase 1 data for ARR-217, its CDH17-targeted ADC, showing a 44.8% objective response rate in heavily pretreated colorectal cancer patients at the 6 mg/kg dose with a 93.1% disease control rate. Safety was generally manageable: Grade 3+ treatment-related adverse events were 20.4% at the 6 mg/kg dose, with no grade 5 TRAEs or ILD observed across 123 patients as of the August 5, 2026 data cutoff. ARR-217, partnered with Lepu Biopharma, has advanced into Phase 1b dose optimization at 5 and 6 mg/kg Q3W, with further data expected in 2027.
Key figures
- Drug Name
- ARR-217 (MRG007)
- Phase Of Trial
- Phase 1 / Phase 1b dose optimization
- Data cutoff
- August 5, 2026
- Dcr crc 6mg
- 93.1% (27/29)
- Orr crc 6mg
- 44.8% (13/29)
- Crc patients
- 113
- Dcr 4mg plus
- 91.8%
- Orr crc 4mg plus
- 34.2% (25/73)
- Patients treated
- 123
- Grade3plus trae 6mg
- 20.4% (10/49)
- Grade3plus trae all doses
- 30.1% (37/123)
- Dose optimization data expected
- 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.